Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
01 juin 2024 08h00 HE
|
Immunocore Holdings plc
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
29 mai 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA,...
Immunocore reports first quarter financial results and provides a business update
08 mai 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7...
Immunocore announces upcoming presentation and posters at ASCO 2024
24 avr. 2024 10h00 HE
|
Immunocore Holdings plc
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be...
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
28 févr. 2024 07h34 HE
|
Immunocore Holdings Limited
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023;...
Immunocore announces upcoming presentation and posters at ESMO 2023
06 oct. 2023 07h01 HE
|
Immunocore Holdings Limited
Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a...
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
03 juin 2023 07h00 HE
|
Immunocore Holdings Limited
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3...
Immunocore is awarded the Prix Galien France award for KIMMTRAK
15 déc. 2022 06h00 HE
|
Immunocore Holdings Limited
Immunocore is awarded the Prix Galien France award for KIMMTRAK Treatment for unresectable or metastatic uveal melanoma, a rare and aggressive form of cancer affecting the eye. (OXFORDSHIRE,...
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
11 nov. 2022 09h00 HE
|
Immunocore Holdings Limited
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of gp100 protein, the target of KIMMTRAK, is...
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
03 août 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 August 2022) Immunocore Holdings plc...